As therapy of PHA1B is only symptomatic so far, these TNF tip peptides, which directly target ENaC, are promising candidates for the treatment of the channelopathy-caused disease PHA1B (118). This evidence concerns the gene TNF and pseudohypoaldosteronism, type IB1, autosomal recessive.